MX2010007342A - Formulaciones de insulina para la liberacion de insulina como una funcion de los niveles de glucosa en el tejido. - Google Patents

Formulaciones de insulina para la liberacion de insulina como una funcion de los niveles de glucosa en el tejido.

Info

Publication number
MX2010007342A
MX2010007342A MX2010007342A MX2010007342A MX2010007342A MX 2010007342 A MX2010007342 A MX 2010007342A MX 2010007342 A MX2010007342 A MX 2010007342A MX 2010007342 A MX2010007342 A MX 2010007342A MX 2010007342 A MX2010007342 A MX 2010007342A
Authority
MX
Mexico
Prior art keywords
insulin
formulation
patient
formulations
release
Prior art date
Application number
MX2010007342A
Other languages
English (en)
Inventor
Solomon S Steiner
Roderike Pohl
Nandini Kashyap
Original Assignee
Biodel Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biodel Inc filed Critical Biodel Inc
Publication of MX2010007342A publication Critical patent/MX2010007342A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones

Abstract

Se describen en la presente formulaciones de insulina inyectables que son capaces de modificar la cantidad de insulina liberada basada en los niveles de glucosa en el tejido del paciente, métodos para hacer y usar estas formulaciones. Las formulaciones se pueden administrar por la vía de la administración subcutánea, intradérmica o intramuscular. En una modalidad preferida, las formulaciones se administran por la vía de la inyección subcutánea. Las formulaciones contienen insulina, un agente oxidante o enzima y un agente reductor o enzima, un diluyente y opcionalmente uno o más agentes de espesamiento. Si un agente de espesamiento está presente en la formulación, el agente de espesamiento incrementa la viscosidad de la formulación después de la administración. De preferencia la formulación contiene una insulina, un diluyente, glucosa oxidasa y peroxidasa. Después de la administración a un paciente, la insulina se libera de las formulaciones como una función del nivel de glucosa en el tejido del paciente, que a su vez mantiene el nivel de glucosa en la sangre del paciente dentro de un intervalo óptimo. La formulación es frecuentemente referida como una formulación "inteligente" puesto que modifica su velocidad de liberación de insulina de acuerdo con las necesidades del paciente en un tiempo particular. En una modalidad preferida, la formulación se diseña para liberar insulina en la circulación sistémica a través del tiempo con un perfil de liberación basal después de la inyección en un paciente. En otra modalidad, la formulación se diseña para liberar insulina en la circulación sistémica a través del tiempo con un perfil de liberación no basal después de la inyección en un paciente, tal como un perfil de liberación de insulina humana regular o un perfil de liberación prandial.
MX2010007342A 2008-01-04 2009-01-05 Formulaciones de insulina para la liberacion de insulina como una funcion de los niveles de glucosa en el tejido. MX2010007342A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1918708P 2008-01-04 2008-01-04
PCT/US2009/030153 WO2009089181A1 (en) 2008-01-04 2009-01-05 Insulin formulations for insulin release as a function of tissue glucose levels

Publications (1)

Publication Number Publication Date
MX2010007342A true MX2010007342A (es) 2010-08-26

Family

ID=40419014

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010007342A MX2010007342A (es) 2008-01-04 2009-01-05 Formulaciones de insulina para la liberacion de insulina como una funcion de los niveles de glucosa en el tejido.

Country Status (10)

Country Link
US (1) US20090175840A1 (es)
EP (1) EP2234644B1 (es)
JP (1) JP5352596B2 (es)
CN (1) CN101951957A (es)
AU (1) AU2009204309B2 (es)
CA (1) CA2711561A1 (es)
HK (1) HK1149195A1 (es)
IL (1) IL206726A0 (es)
MX (1) MX2010007342A (es)
WO (1) WO2009089181A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010028055A1 (en) * 2008-09-02 2010-03-11 Biodel, Inc. Insulin with a basal release profile
PT2349324T (pt) 2008-10-17 2017-12-06 Sanofi Aventis Deutschland Combinação de uma insulina e de um agonista do glp-1
US9060927B2 (en) * 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
EP2458378B1 (en) * 2009-07-21 2017-12-06 Sekisui Medical Co., Ltd. Insulin measurement method
PL3345593T3 (pl) 2009-11-13 2024-04-08 Sanofi-Aventis Deutschland Gmbh Kompozycja farmaceutyczna zawierająca desPro36-eksendynę-4(1-39)-Lys6-NH2 i metioninę
PE20121362A1 (es) 2009-11-13 2012-10-17 Sanofi Aventis Deutschland Composicion farmaceutica que comprende despro36exendina-4(1-39)-lys6-nh2, insulina gly(a21)-arg(b31)-arg(b32) y metionina
US8637458B2 (en) 2010-05-12 2014-01-28 Biodel Inc. Insulin with a stable basal release profile
AU2011202239C1 (en) * 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
WO2011156476A2 (en) * 2010-06-08 2011-12-15 Biodel Inc. Insulin with a basal release profile
WO2012028172A1 (en) 2010-08-30 2012-03-08 Sanofi-Aventis Deutschland Gmbh Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
CN102188367B (zh) * 2011-01-05 2012-11-07 山东新时代药业有限公司 一种甘精胰岛素注射液及其制备方法
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
AU2012300978B2 (en) 2011-08-29 2017-04-27 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
CN103191417A (zh) * 2012-01-05 2013-07-10 四川大学 载有胰岛素聚集体的长效控制血糖浓度的药物控释体系及制备方法
AU2013346624B2 (en) 2012-11-13 2018-08-09 Adocia Quick-acting insulin formulation including a substituted anionic compound
WO2014096985A2 (en) 2012-12-19 2014-06-26 Wockhardt Limited A stable aqueous composition comprising human insulin or an analogue or derivative thereof
BR112015013223A2 (pt) * 2012-12-26 2017-07-11 Wockhardt Ltd composição farmacêutica
ES2709339T3 (es) 2013-04-03 2019-04-16 Sanofi Sa Tratamiento de la diabetes mellitus mediante formulaciones de insulinas de acción prolongada
CN104587455A (zh) * 2013-10-31 2015-05-06 江苏万邦生化医药股份有限公司 一种胰岛素制剂
SG11201607936QA (en) * 2014-04-25 2016-11-29 Sanofi Sa New administration routes of insulin, insulin analogs or derivatives of insulin
WO2016001862A1 (en) 2014-07-04 2016-01-07 Wockhardt Limited Extended release formulations of insulins
EP3229828B1 (en) 2014-12-12 2023-04-05 Sanofi-Aventis Deutschland GmbH Insulin glargine/lixisenatide fixed ratio formulation
CN104688677B (zh) * 2015-02-05 2018-02-09 通化东宝药业股份有限公司 一种稳定的甘精胰岛素注射液及其制备方法
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患之治療
CA3045882A1 (en) 2016-12-05 2018-06-14 North Carolina State University Core-shell microneedle devices and uses thereof
CN109464657A (zh) * 2018-11-26 2019-03-15 常州工程职业技术学院 一种嵌段共聚物载胰岛素控制释放的方法

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2143590A (en) * 1936-09-26 1939-01-10 Univ Alberta Insulin preparation and process of producing crystals of insulin
US2626228A (en) * 1945-05-17 1953-01-20 Novo Terapeutisk Labor As Method of producing crystalline insulin
US2819999A (en) * 1953-11-13 1958-01-14 Novo Terapeutisk Labor As Process for crystallization of insulin using freeze dried insulin as seeding material
US3649456A (en) * 1969-09-08 1972-03-14 Rohm & Haas Separation of polypeptide substances with macroreticular resins
FR2224175B1 (es) * 1973-04-04 1978-04-14 Isf Spa
US4153689A (en) * 1975-06-13 1979-05-08 Takeda Chemical Industries, Ltd. Stable insulin preparation for nasal administration
US4211769A (en) * 1977-08-24 1980-07-08 Takeda Chemical Industries, Ltd. Preparations for vaginal administration
US4377482A (en) * 1978-04-28 1983-03-22 Salk Institute For Biological Studies Mobile phase for liquid chromatography
US4196196A (en) * 1978-06-19 1980-04-01 Tiholiz Ivan C Divalen/monovalent bipolar cation therapy for enhancement of tissue perfusion and reperfusion in disease states
US4272398A (en) * 1978-08-17 1981-06-09 The United States Of America As Represented By The Secretary Of Agriculture Microencapsulation process
JPS55138393A (en) * 1979-04-13 1980-10-29 Shionogi & Co Ltd Semisynthesis of insulin
US4343898A (en) * 1980-02-11 1982-08-10 Novo Industri A/S Process for preparing esters of human insulin
US4364385A (en) * 1981-03-13 1982-12-21 Lossef Steven V Insulin delivery device
KR890000664B1 (ko) * 1981-10-19 1989-03-22 바리 안소니 뉴우샘 미분된 베클로메타손 디프로피오네이트 일수화물의 제조방법
US4459226A (en) * 1982-02-26 1984-07-10 Eli Lilly And Company Process for recovering insulin
US4659696A (en) * 1982-04-30 1987-04-21 Takeda Chemical Industries, Ltd. Pharmaceutical composition and its nasal or vaginal use
US4946828A (en) * 1985-03-12 1990-08-07 Novo Nordisk A/S Novel insulin peptides
US5785989A (en) * 1985-05-01 1998-07-28 University Utah Research Foundation Compositions and methods of manufacturing of oral dissolvable medicaments
US5042975A (en) * 1986-07-25 1991-08-27 Rutgers, The State University Of New Jersey Iontotherapeutic device and process and iontotherapeutic unit dose
EP0318512B1 (en) * 1986-08-18 1998-06-17 Emisphere Technologies, Inc. Delivery systems for pharmacological agents
USRE35862E (en) * 1986-08-18 1998-07-28 Emisphere Technologies, Inc. Delivery systems for pharmacological agents encapsulated with proteinoids
DE3779221D1 (de) * 1986-08-19 1992-06-25 Genentech Inc Einrichtung und dispersion zum intrapulmonalen eingeben von polypeptidwuchsstoffen und -zytokinen.
US4861627A (en) * 1987-05-01 1989-08-29 Massachusetts Institute Of Technology Preparation of multiwall polymeric microcapsules
GB8723846D0 (en) * 1987-10-10 1987-11-11 Danbiosyst Ltd Bioadhesive microsphere drug delivery system
US5006343A (en) * 1988-12-29 1991-04-09 Benson Bradley J Pulmonary administration of pharmaceutically active substances
US5514646A (en) * 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
US5188837A (en) * 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
IL99699A (en) * 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
AU1442592A (en) * 1991-02-20 1992-09-15 Nova Pharmaceutical Corporation Controlled release microparticulate delivery system for proteins
US5492112A (en) * 1991-05-20 1996-02-20 Dura Pharmaceuticals, Inc. Dry powder inhaler
CA2070061C (en) * 1991-06-07 2004-02-10 Shigeyuki Takama Physiologically active polypeptide-containing pharmaceutical composition
US6063910A (en) * 1991-11-14 2000-05-16 The Trustees Of Princeton University Preparation of protein microparticles by supercritical fluid precipitation
US5329976A (en) * 1991-12-09 1994-07-19 Habley Medical Technology Corporation Syringe-filling and medication mixing dispenser
JP3121080B2 (ja) * 1991-12-19 2000-12-25 アール・ピー・シーラー コーポレイション カプセル封入用溶液
US5352461A (en) * 1992-03-11 1994-10-04 Pharmaceutical Discovery Corporation Self assembling diketopiperazine drug delivery system
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5785049A (en) * 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
US5888477A (en) * 1993-01-29 1999-03-30 Aradigm Corporation Use of monomeric insulin as a means for improving the bioavailability of inhaled insulin
US5747445A (en) * 1993-06-24 1998-05-05 Astra Aktiebolag Therapeutic preparation for inhalation
IS1796B (is) * 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
EP0804174A4 (en) * 1993-07-21 1998-09-09 Univ Kentucky Res Found MULTI-CHAMBER HARD CAPSULES WITH CONTROLLED DELIVERY CHARACTERISTICS
US5534488A (en) * 1993-08-13 1996-07-09 Eli Lilly And Company Insulin formulation
CA2171424C (en) * 1993-09-17 2002-06-04 Svend Havelund Acylated insulin
US5484606A (en) * 1994-01-24 1996-01-16 The Procter & Gamble Company Process for reducing the precipitation of difficulty soluble pharmaceutical actives
ES2218543T3 (es) * 1994-03-07 2004-11-16 Nektar Therapeutics Procedimiento y preparacion para la administracion de insulina por via pulmonar.
US6051256A (en) * 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
US6395744B1 (en) * 1994-04-22 2002-05-28 Queen's University At Kingston Method and compositions for the treatment or amelioration of female sexual dysfunction
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5547929A (en) * 1994-09-12 1996-08-20 Eli Lilly And Company Insulin analog formulations
CA2206053A1 (en) * 1994-12-01 1996-06-06 Toyama Chemical Co., Ltd. Novel 2,3-diketopiperazine derivatives or their salts
US5901703A (en) * 1995-02-06 1999-05-11 Unisia Jecs Corporation Medicine administering device for nasal cavities
US5653961A (en) * 1995-03-31 1997-08-05 Minnesota Mining And Manufacturing Company Butixocort aerosol formulations in hydrofluorocarbon propellant
US6428771B1 (en) * 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
US5653987A (en) * 1995-05-16 1997-08-05 Modi; Pankaj Liquid formulations for proteinic pharmaceuticals
CA2236579C (en) * 1995-11-13 2009-06-30 Minimed, Inc. Methods and compositions for the delivery of monomeric proteins
DE19545257A1 (de) * 1995-11-24 1997-06-19 Schering Ag Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln
USRE37053E1 (en) * 1996-05-24 2001-02-13 Massachusetts Institute Of Technology Particles incorporating surfactants for pulmonary drug delivery
US6503480B1 (en) * 1997-05-23 2003-01-07 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6254854B1 (en) * 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
US5783556A (en) * 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
US5898028A (en) * 1997-03-20 1999-04-27 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
WO1999016417A1 (en) * 1997-10-01 1999-04-08 Flemington Pharmaceutical Corporation Buccal, polar and non-polar spray or capsule
US6451346B1 (en) * 1998-12-23 2002-09-17 Amgen Inc Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents
US6552024B1 (en) * 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7169889B1 (en) * 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
US6444226B1 (en) * 1999-06-29 2002-09-03 Pharmaceutical Discovery Corporation Purification and stabilization of peptide and protein pharmaceutical agents
US6264981B1 (en) * 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
MXPA02004193A (es) * 1999-10-29 2002-12-13 Inhale Therapeutic Syst Composiciones de polvo seco que tienen caracteristicas de dispersion mejoradas.
ES2305057T3 (es) * 2000-02-28 2008-11-01 Pharmakodex Limited Dispositivo para la administracion de farmacos orales.
US6432383B1 (en) * 2000-03-30 2002-08-13 Generex Pharmaceuticals Incorporated Method for administering insulin
US7316999B2 (en) * 2000-06-02 2008-01-08 Novo Nordisk A/S Glucose dependent release of insulin from glucose sensing insulin derivatives
GB0129489D0 (en) * 2001-12-10 2002-01-30 Quadrant Healthcare Uk Ltd Sustained-release compositions
US7255102B2 (en) * 2002-02-01 2007-08-14 Generex Pharmaceuticals Inc. Metered dose spray device for use with macromolecular pharmaceutical agents such as insulin
EP1506003A1 (en) * 2002-05-07 2005-02-16 Novo Nordisk A/S Soluble formulations comprising insulin aspart and insulin detemir
DE10227232A1 (de) * 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
DE10235168A1 (de) * 2002-08-01 2004-02-12 Aventis Pharma Deutschland Gmbh Verfahren zur Reinigung von Preproinsulin
WO2004041118A2 (en) * 2002-10-31 2004-05-21 Umd, Inc. Therapeutic compositions for drug delivery to and through covering epithelia
AU2003261633A1 (en) * 2003-02-12 2004-09-06 R And P Korea Co., Ltd. Solvent system of hardly soluble drug with improved elution rate
BRPI0414539B8 (pt) * 2003-09-19 2021-05-25 Novo Nordisk As composto, composição farmacêutica, e, uso de um composto
US7192919B2 (en) * 2004-01-07 2007-03-20 Stelios Tzannis Sustained release compositions for delivery of pharmaceutical proteins
KR100985126B1 (ko) * 2004-01-12 2010-10-05 맨카인드 코포레이션 제2형 당뇨병에서 혈청 프로인슐린 수치의 감소 방법
US20080090753A1 (en) * 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
US20080085298A1 (en) * 2004-03-12 2008-04-10 Biodel, Inc. Rapid Mucosal Gel or Film Insulin Compositions
US20080096800A1 (en) * 2004-03-12 2008-04-24 Biodel, Inc. Rapid mucosal gel or film insulin compositions
WO2006088473A2 (en) * 2004-04-23 2006-08-24 Panduranga Rao Koritala Microcapsules and nanocapsules for the transmucosal delivery of therapeutic and diagnostic agents
US7713929B2 (en) * 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
US8084420B2 (en) * 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
US8093207B2 (en) * 2005-12-09 2012-01-10 Unigene Laboratories, Inc. Fast-acting oral peptide pharmaceutical products
US7718609B2 (en) * 2006-04-12 2010-05-18 Biodel Inc. Rapid acting and long acting insulin combination formulations
CA2660029A1 (en) * 2006-08-04 2008-02-07 Nastech Pharmaceutical Company Inc. Compositions for intranasal delivery of human insulin and uses thereof

Also Published As

Publication number Publication date
WO2009089181A1 (en) 2009-07-16
JP5352596B2 (ja) 2013-11-27
US20090175840A1 (en) 2009-07-09
AU2009204309B2 (en) 2012-11-22
CN101951957A (zh) 2011-01-19
JP2011508786A (ja) 2011-03-17
HK1149195A1 (en) 2011-11-25
EP2234644A1 (en) 2010-10-06
AU2009204309A1 (en) 2009-07-16
IL206726A0 (en) 2010-12-30
CA2711561A1 (en) 2009-07-16
EP2234644B1 (en) 2013-07-31

Similar Documents

Publication Publication Date Title
MX2010007342A (es) Formulaciones de insulina para la liberacion de insulina como una funcion de los niveles de glucosa en el tejido.
PL385586A1 (pl) Nowe analogi insuliny o przedłużonym działaniu
WO2013123492A3 (en) Glucose-responsive microgels for closed loop insulin delivery
PH12017501910A1 (en) Glucose-responsive insulin delivery system using hyoxia-sensitive nanocomposites
WO2008124522A3 (en) Amylin formulations
MX2011009174A (es) Formulaciones de insulina para captacion rapida.
EP2829265A3 (en) Novel formulations for treatment of migraine
BR112013032265A2 (pt) métodos de infusão de insulina subcutânea contínua com uma enzima de degradação do hialuronano
BR0211894A (pt) Métodod de minimização e de redução dos nìveis médios de glucose, de tratamento de uma condição médica causada por nìveis elevados de glucose no sangue e de redução do valor hba1c em paciente dependente de insulina
WO2010056922A3 (en) Systems and methods for delivery of biologically active agents
MX2010003776A (es) Composiciones de insulina inyectables de accion rapida.
NZ710157A (en) Use of guanethidine for treating hypertension by local vascular delivery
EP2676691A3 (en) Delivery of viscous formulations by needle-free injection
WO2010005680A3 (en) Transdermal local anesthetic patch with injection port
MXPA05006634A (es) Fluidos de dialisis biocompatibles que contienen icodextrinas.
EP3488885A3 (en) Combination of needle hub and shell for use with pen injector
WO2013078257A8 (en) Implantable solid-liquig drug delivery apparatus, formulations, and methods of use
WO2005113016A3 (en) Modulation of glucose-6-phosphatase translocase expression
EP2907535A3 (en) Syringe type pump
WO2007105203A3 (en) Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels
IN2015DN01454A (es)
MX2021001586A (es) Plataforma de estabilizacion de cateter, sistemas y metodos.
WO2011056447A3 (en) Methods and kits for preventing hypoglycemia
MX2019009922A (es) Formulaciones a base de aceite para suministro sublingual y bucal.
DE60215866D1 (de) Medikament, enthaltend cyanidin-3-glykosid als wirkstoff gegen fettsucht und diabetes

Legal Events

Date Code Title Description
FA Abandonment or withdrawal